drugset / Trial / NCT00141219

Pregabalin Peripheral Neuropathic Pain Study

NCT00141219

Phase 3 Completed 241 enrolled Viatris Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

To evaluate the efficacy of pregabalin, using a flexible, optimized dose schedule with dose adjustment based on Daily Pain Rating Scale (DPRS), compared to placebo in subjects with peripheral neuropathic pain.

Timeline

Start
2005-12
Primary completion
2007-12
Completion
2007-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Pregabalin Small molecule 150 mg
Subject Pregabalin Small molecule 600 mg